Antitumor Effect By Interleukin-11 Receptor Alpha-Locus Chemokine/Ccl27, Introduced Into Tumor Cells Through A Recombinant Adenovirus Vector

Jian-Qing Gao,Yasuhiro Tsuda,Kazufumi Katayama,Takashi Nakayama,Yutaka Hatanaka,Yoichi Tani,Hiroyuki Mizuguchi,Takao Hayakawa,Osamu Yoshie,Yasuo Tsutsumi,Tadanori Mayumi,Shinsaku Nakagawa

IF: 11.2

2003-01-01

Cancer Research

Abstract:In this study, we examined. antitumor activity of a mouse CC chemokine ILC/CCL27 and a mouse CX3C chemokine fractalkine/CX(3)CL1 in vivo. We generated recombinant adenovirus vectors with a fiber mutation, encoding mILC (Ad-RGD-mILC) and mFKN (Ad-RGD-mFKN). We confirmed tumor cells infected with Ad-RGD-mILC and Ad-RGD-mFKN to express and release these chemokines. Tumor rejection experiments in vivo were carried out by inoculating OV-HM cells infected with Ad-RGD-mILC or Ad-RGD-mFKN into immunocompetent mice. mILC significantly suppressed the tumor growth, whereas no such significant effect was observed by mFKN. The antitumor activity induced by mILC was T cell dependent, involving both CD4(+) and CD8(+) T cells. Immunohistochemical analysis revealed accumulation of both CD3(+) lymphocytes and NK cells in the tumor tissue transduced with mILC and mFKN. However, there was a significant difference in the distribution of infiltrating cells. Furthermore, mFKN appeared to hake an angiogenic activity, which might have masked its tumor suppressive activity. Collectively, ILC/CCL27 may be a good candidate molecule for cancer gene therapy.